Duke-Robert J. Margolis, MD, Institute for Health Policy

04/03/2026

Check out the new draft agenda for our upcoming event, "Increasing Access to Nonprescription Drugs!" Speakers will explore opportunities to improve public health with nonprescription treatments, evidence generation to demonstrate safety and efficacy in the nonprescription setting, and innovation to enable increased access to nonprescription drugs. Read the draft agenda and register here: https://duke.is/p/4g3b

04/01/2026

As clinical AI tools are embedded in care delivery, new opportunities to improve patient care increase along with new patient safety risks. Duke-Margolis and Duke Health AI Evaluation & Governance have released a white paper that explores this issue in detail, highlighting recommendations for health systems to create effective AI risk management and patient safety event reporting. Read more here: https://duke.is/m/rrnn

03/25/2026

Registration closes soon! Join us on Monday for the third workshop in the RISE series, co-convened with the FDA Rare Disease Innovation Hub, where our expert speakers will explore the potential of data sharing to advance rare disease clinical trials and medical product development. Space is filling fast for in-person attendance, so be sure to secure your spot: https://duke.is/2/t6dr

03/18/2026

A new hybrid meeting has been announced! Join us on April 23 for this event, hosted under a cooperative agreement with the U.S. Food and Drug Administration, that will explore opportunities to increase access to nonprescription drugs. For more opportunities to network with your peers, we invite you to attend in-person at the National Press Club. Space is limited! Register today: https://duke.is/p/4g3b

03/17/2026

Hear the latest in clinical trial innovation at our upcoming hybrid workshop, co-convened with the U.S. Food and Drug Administration (FDA) CDER Center for Clinical Trial Innovation (C3TI). On April 14, we are gathering expert speakers to discuss C3TI activities as well as strategies to advance broader adoption of innovative approaches in the design and conduct of clinical trials. Learn more and register here: https://duke.is/m/qy4t

03/13/2026

Don't miss the 2026 Duke MBA Health Care Conference! The Duke Fuqua School of Business Health Care Club is hosting their annual conference on March 25 to discuss health care innovation. Dev Sangvai, Secretary of the North Carolina Department of Health and Human Services, is the keynote speaker at the event. Hear from our Senior Research Director, Marianne Hamilton Lopez, who will discuss cell and gene therapies, as well as Core Faculty member David Ridley as he moderates a panel discussion on emerging markets. Learn more and register here:

From Innovation to Impact: The Business of Transforming Healthcare 3.25.2026 Go to Duke MBA Health Care Club

03/11/2026

Speakers have been announced! Join us in just a few weeks for a hybrid workshop exploring how data sharing can advance rare disease therapy development. We're gathering a group of expert speakers at the National Press Club in Washington, DC, on March 30 to discuss this issue and share case examples of data sharing in practice, featuring different types of data. Read the draft agenda and register here: https://duke.is/2/t6dr

03/05/2026

In just a few weeks, we are co-hosting an event with the Duke Health AI Evaluation & Governance Program! Clinical AI tools are increasingly embedded in care delivery, creating new opportunities to improve outcomes but also new patient safety risks that require proactive risk management. Join us for a webinar on March 24 that will explore strategies to protect patients in the age of AI: https://duke.is/5/cg7u

02/26/2026

The new Health Value Evidence Quality (HV-EQ) Framework from our Capital Impact Council (CIC) outlines guidance to help assure private investments in health care deliver health value alongside financial returns: https://duke.is/HVEQ

In particular, the framework identifies four stages of evidence quality and demonstrates how an intentional HV-EQ strategy can be incorporated at each stage of an investment’s life cycle. It also highlights 11 case examples from CIC members that illustrate the framework’s practical application in health care investments. Read the case examples here: https://healthpolicy.duke.edu/CIC

02/24/2026

In his recent testimony to the U.S.–China Economic and Security Review Commission, Visiting Fellow Chan Harjivan underscored that America’s drug supply chain is a matter of national security, not just health policy. The COVID-19 pandemic exposed how disruptions can cascade into widespread, long-term drug shortages, revealing geopolitical risks and structural fragility across the supply chain. Dr. Harjivan outlined a few recommendations to address this issue, including:

- sustained U.S. investment in domestic and allied manufacturing capacity,
- AI-enabled biomanufacturing
- stronger transparency requirements, and
- long-term policy incentives to build resilience and reduce strategic vulnerabilities.

Read the full written testimony here: https://duke.is/z/v5hu

02/23/2026

Duke-Margolis has released a new white paper! The authors discuss best practices for curation of real-world data sourced from electronic health records with three key considerations in mind:

- Defining EHR-sourced data curation as both a concept and practice;
- Implementing real-world best practices and tools to address pertinent regulatory concerns for curation; and
- Involving artificial intelligence (AI) in the process of EHR-sourced data curation.

Read the paper here: https://duke.is/b/n2dv

02/19/2026

Our next public event is today, starting at 3pm ET! One of the collaborative efforts that will be highlighted in today's webinar is the West Health and Duke-Margolis Accelerator's Accountable Care Learning Hub. The Accelerator provides a number of useful resources for accountable care transformation; learn more about the initiative here: https://duke.is/WestDMIAccelerator